Outcomes of HCV treatment: Who does well and who does not?
Journal
Journal of Gastroenterology and Hepatology (Australia)
Journal Volume
25
Journal Issue
5
Pages
846-848
Date Issued
2010
Author(s)
Hsu C.-S.
SDGs
Other Subjects
alanine aminotransferase; aspartate aminotransferase; interferon; interleukin 28; peginterferon; ribavirin; virus RNA; antivirus agent; virus RNA; interleukin 28B; peginterferon; ribavirin; accuracy; amino acid substitution; analytic method; antiviral therapy; cancer risk; chronic hepatitis; drug dosage form comparison; drug efficacy; editorial; genetic association; genetic polymorphism; genotype; hepatitis C; human; immunotherapy; insulin resistance; liver biopsy; liver fibrosis; liver stiffness; patient compliance; predictor variable; priority journal; recurrence risk; risk assessment; single nucleotide polymorphism; treatment duration; treatment outcome; treatment response; virus hepatitis; virus load; blood; complication; drug combination; drug effects; genetics; Hepacivirus; Hepatitis C, Chronic; liver; liver cirrhosis; pathology; patient selection; recurrent disease; risk factor; severity of illness index; time; virology; age; algorithm; aminotransferase blood level; antiviral therapy; Asian; body mass; chronic hepatitis B; chronic hepatitis C; clinical practice; Editorial; elastography; ethnicity; gold standard; health care quality; Hepatitis C virus genotype 1; liver histology; personalized medicine; prognosis; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Patient Selection; Recurrence; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load
Publisher
Blackwell Publishing
Type
editorial